This article was originally published in The Gray Sheet
Nov. 23-24 hearing is scheduled in Chicago federal court on plaintiff's motion for a preliminary injunction against Alza Corp. and Abbott Laboratories to block the proposed merger pending dissemination to Alza shareholders the facts concerning the status of Abbott's negotiations with FDA on manufacturing deficiencies at Abbott's Lake County, Illinois facilities, Abbott reports Oct. 28. Abbott announced continuing difficulties with FDA on Sept. 28 (1"The Gray Sheet" Oct. 4, p. 16), seven days after Alza shareholders approved the merger
You may also be interested in...
Discussions between Abbott Labs and FDA over a proposed consent decree that could halt production of certain diagnostic products likely relate to quality system regulations (QSR) violations detected over a year ago at the firm's Abbott Park, Illinois facility.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.